R&D Insights: How Bio-Techne Corporation and Wave Life Sciences Ltd. Allocate Funds

Biotech R&D: Bio-Techne vs. Wave Life Sciences

__timestampBio-Techne CorporationWave Life Sciences Ltd.
Wednesday, January 1, 2014309450002395000
Thursday, January 1, 2015408530009057000
Friday, January 1, 20164518700040818000
Sunday, January 1, 20175351400079309000
Monday, January 1, 201855329000134428000
Tuesday, January 1, 201962413000175431000
Wednesday, January 1, 202065192000130944000
Friday, January 1, 202170603000121875000
Saturday, January 1, 202287140000115856000
Sunday, January 1, 202392493000130009000
Monday, January 1, 202496664000
Loading chart...

Data in motion

R&D Spending: A Tale of Two Biotech Innovators

In the dynamic world of biotechnology, research and development (R&D) is the lifeblood of innovation. Bio-Techne Corporation and Wave Life Sciences Ltd. exemplify this commitment, albeit with distinct trajectories. From 2014 to 2023, Bio-Techne's R&D expenses surged by approximately 212%, reflecting a steady annual growth. In contrast, Wave Life Sciences experienced a more volatile journey, with a staggering 5,327% increase from 2014 to 2022, before data for 2024 became unavailable.

A Decade of Investment

Bio-Techne's consistent investment underscores its strategic focus on sustainable growth, while Wave Life Sciences' fluctuating expenses highlight its aggressive pursuit of breakthrough therapies. By 2023, Bio-Techne's R&D spending reached nearly 92 million, while Wave Life Sciences peaked at 130 million in 2022. This comparison not only showcases their financial strategies but also offers a glimpse into the future of biotech innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025